Difference between revisions of "Atypical hemolytic uremic syndrome"
Jump to navigation
Jump to search
(Created page with "To be completed ===References=== # Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, e...") |
m |
||
| Line 1: | Line 1: | ||
| − | + | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | |
| + | |||
| + | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
| + | |||
| + | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| + | |- | ||
| + | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | ||
| + | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
| + | |} | ||
| + | {{TOC limit|limit=3}} | ||
| + | |||
| + | =All lines of treatment= | ||
| + | |||
| + | ==Eculizumab (Soliris) {{#subobject:24195b|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#toc|back to top]] | ||
| + | |} | ||
| + | |||
| + | ===Regimen {{#subobject:8ceb84|Variant=1}}=== | ||
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |- | ||
| + | |[http://www.bloodjournal.org/content/125/21/3253.long Cofiell et al. 2015] | ||
| + | |<span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Non-randomized</span> | ||
| + | |- | ||
| + | |} | ||
| + | |||
| + | ''Eligible patients had platelet counts < 150 × 10<sup>9</sup>/L, hemoglobin levels ≤ lower limit of normal, LDH levels ≥ 1.5x upper limit of normal, serum creatinine levels ≥ upper limit of normal, ADAMTS13 activity ≥ 5%, and no positive Shiga toxin-producing ''Escherichia coli'' test.'' | ||
| + | |||
| + | *[[Eculizumab (Soliris)]] 900 mg IV once per week for 4 weeks, then 1200 mg IV once on week 5, then 1200 mg IV every 2 weeks | ||
| + | |||
| + | Supportive medications: | ||
| + | * Patients were vaccinated against ''Neisseria meningitidis'' or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose | ||
| + | |||
| + | '''Indefinite course''' | ||
===References=== | ===References=== | ||
| − | # Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/21/3253.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25833956 PubMed] | + | # Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/21/3253.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25833956 PubMed] |
Revision as of 01:22, 13 March 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
2 regimens on this page
2 variants on this page
|
All lines of treatment
Eculizumab (Soliris)
| back to top |
Regimen
| Study | Evidence |
| Cofiell et al. 2015 | Non-randomized |
Eligible patients had platelet counts < 150 × 109/L, hemoglobin levels ≤ lower limit of normal, LDH levels ≥ 1.5x upper limit of normal, serum creatinine levels ≥ upper limit of normal, ADAMTS13 activity ≥ 5%, and no positive Shiga toxin-producing Escherichia coli test.
- Eculizumab (Soliris) 900 mg IV once per week for 4 weeks, then 1200 mg IV once on week 5, then 1200 mg IV every 2 weeks
Supportive medications:
- Patients were vaccinated against Neisseria meningitidis or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose
Indefinite course
References
- Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. link to original article contains verified protocol PubMed